Capital International Investors Bluebird Bio, Inc. Transaction History

Capital International Investors

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $18.7 Million - $38.2 Million	-1,127,687 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $8,387 - $11,565	305 Added 0.03%	1,127,687 $48.8 Million
Q3 2020 Nov 13, 2020	SELL	$34.44 - $43.75 $137 - $175	-4 Reduced -0.0%	1,127,382 $60.8 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $7.25 Million - $12.3 Million	267,160 Added 31.06%	1,127,386 $68.8 Million
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $16.7 Million - $40.6 Million	-639,832 Reduced 42.65%	860,226 $39.5 Million
Q4 2019 Feb 18, 2020	SELL	$46.96 - $61.67 $185 Million - $243 Million	-3,940,286 Reduced 72.43%	1,500,058 $132 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $20.9 Million - $32.7 Million	351,340 Added 6.9%	5,440,344 $500 Million
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $2.34 Million - $3.25 Million	-30,866 Reduced 0.6%	5,089,004 $647 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $4.45 Million - $7.2 Million	69,112 Added 1.37%	5,119,870 $806 Million
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $106 Million - $167 Million	1,790,122 Added 54.9%	5,050,758 $501 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $189 Million - $250 Million	2,130,927 Added 188.63%	3,260,636 $476 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $11.3 Million - $14.4 Million	112,961 Added 11.11%	1,129,709 $177 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $108 Million - $153 Million	1,016,748 New	1,016,748 $174 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.